EBS

Emergent Bio
NYSE

Real-time Quotes | Nasdaq Last Sale

94.23
-0.25
-0.26%
After Hours: 93.75 -0.48 -0.51% 19:53 07/10 EDT
OPEN
94.48
PREV CLOSE
94.48
HIGH
94.98
LOW
91.88
VOLUME
527.46K
TURNOVER
--
52 WEEK HIGH
96.52
52 WEEK LOW
39.11
MARKET CAP
4.94B
P/E (TTM)
72.76
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EBS stock price target is 83.17 with a high estimate of 93.00 and a low estimate of 64.00.

EPS

EBS News

More
Emergent Biosolutions (EBS) Stock Sinks As Market Gains: What You Should Know
Emergent Biosolutions (EBS) closed at $94.23 in the latest trading session, marking a -0.26% move from the prior day.
Zacks · 6h ago
Is Emergent Biosolutions (EBS) Stock Outpacing Its Medical Peers This Year?
Is (EBS) Outperforming Other Medical Stocks This Year?
Zacks · 12h ago
Emergent (EBS) Stock Up Year to Date on Coronavirus Vaccine Deals
Emergent (EBS) inks deals with multiple companies to provide manufacturing services for helping them develop COVID-19 vaccine.
Zacks · 1d ago
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 1d ago
Is Vaxart Stock a Buy?
MotleyFool.com · 1d ago
Emergent Bio and Mt. Sinai to test convalescent plasma for COVID-19
Seeking Alpha - Article · 2d ago
Emergent BioSolutions, Mount Sinai to test COVID-19 blood plasma as preventive treatment
Seeking Alpha - Article · 2d ago
Emergent BioSolutions Gets Deeper Into Covid-19 Deals
Barrons.com · 2d ago

Industry

Pharmaceuticals
-0.31%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About EBS

Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).
More

Webull offers kinds of Emergent Biosolutions Inc stock information, including NYSE:EBS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EBS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EBS stock methods without spending real money on the virtual paper trading platform.